Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. - Wikidata - wikimedia - TriplyDB

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

http://www.wikidata.org/entity/Q35130437

about

Selective gene silencing by viral delivery of short hairpin RNA The dicey role of Dicer: implications for RNAi therapy Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death siRNA Delivery by Stimuli-Sensitive Nanocarriers Targeting angiogenesis in gynecologic cancers Preclinical and clinical development of siRNA-based therapeutics The ZNF304-integrin axis protects against anoikis in cancer Progress toward in vivo use of siRNAs-II Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis Identification of novel therapeutic targets in microdissected clear cell ovarian cancers EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.Advances in Systemic siRNA Delivery Targeting SRC in mucinous ovarian carcinoma.Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer.Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis Changes in gene expression and cellular architecture in an ovarian cancer progression model.Engineering of monobody conjugates for human EphA2-specific optical imaging.Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.Targeted gene silencing using RGD-labeled chitosan nanoparticles.Regulation of tumor angiogenesis by EZH2.Stem cell pathways contribute to clinical chemoresistance in ovarian cancer Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.Efficient and targeted delivery of siRNA in vivo.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis Delivery of siRNA therapeutics: barriers and carriers.Significance and applications of nanoparticles in siRNA delivery for cancer therapy.Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Targeted delivery of siRNA into breast cancer cells via phage fusion proteins.Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.Microenvironment and pathogenesis of epithelial ovarian cancer

P2860

Q21245112-AF4A1500-3908-40FA-8F57-0FF835627220 Q24597854-24D5A182-6B0A-42EE-9629-D3105E74C15D Q24632721-0FE711A4-A158-4AFC-9922-B9D9BE5F144D Q26781212-51F9EFD7-0FAE-41AC-B9A2-173F0F5818EF Q26824766-CB45AF25-8D08-4ABC-9391-3BBA7DDB253A Q28085290-40BD1E5A-997A-431F-A29C-9686C79008ED Q28115264-B4B1D188-4807-48AE-B578-4D6AA174817F Q28255877-BBAA5F32-97D0-4D75-AAEE-2277018C8BC4 Q28271388-43130B3D-A5CE-461D-AA35-1D86C4D9E584 Q28307739-3A7238D7-B674-4ABA-AF02-B50A8BA7A348 Q28742873-79AA7CD1-A450-4904-8C1A-E54793E8ED31 Q30405442-60346F0A-B5AE-4433-88BC-5BF9F43A82F5 Q30483685-A5898CA1-9901-4F36-B00B-7D16970BD2D9 Q30541608-6734C8A8-BB9F-4D4D-9715-CCC09540B2CE Q33589931-412EC138-3B55-4CE2-9FC2-312020AFF7DF Q33613316-96A0B109-793D-4ABF-A752-ABF77B5590EE Q33638051-9FBC640D-7B2B-42BB-85AA-642C3678335F Q33647661-F668423C-9CBB-45F0-AC81-CF131B0A147F Q33815723-FA88FE85-7707-4781-BCB8-9A9455D44A31 Q33842047-71760EB5-2BC8-4149-AA0E-C13CBBD2631B Q33884270-ABA4594A-1050-4B00-B22C-E341B7A58955 Q33911213-44CB7D64-8849-4B7E-B591-C54042354328 Q34031859-2D6140B4-EDC4-4D17-A9DE-0A4AE678CBFA Q34073170-B76682E8-040A-488B-99EC-FC7F4FDBD290 Q34092005-7168921D-B1DE-4F84-AAD9-ABF8F7E1AC04 Q34104147-7CCF3687-AF61-4367-8330-9B0D668ECC58 Q34109901-37D7590B-7A98-401D-9299-5718CA177BDD Q34149828-5A3F5F79-FE8F-4DA0-9A46-4B062D166689 Q34165321-BF6019A3-9DE6-46B6-9C4E-2AE21548D59D Q34285076-5081F88F-036F-4616-A289-47D1B6DC518F Q34293708-E5A9663C-1571-4816-B9DA-4BA7C303D57A Q34297263-2D360B55-9102-4176-A304-15912846A817 Q34420393-E61D3997-CD8B-4A01-AA9E-D896EE8995B5 Q34469271-56B64699-1473-4633-8B42-D53A59C07198 Q34501858-6F8580A7-E55B-47ED-B577-0947BA1ABACA Q34763617-017F5090-BC7E-4389-BEA7-85BC71485681 Q34979610-D3BB9DDB-6E7B-42F0-BF59-27E4613AA46C Q35024933-9C25F395-8EC7-4151-ABC9-0EA578772CB0 Q35093687-C9495299-91FF-4CA3-9484-3023B48AC5B5 Q35419057-C12A0BA2-AFEC-4A23-B41D-D160D1AF4DFF

P2860

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

http://www.wikidata.org/entity/Q35130437

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy.

@ast

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy.

@en

type

label

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy.

@ast

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy.

@en

prefLabel

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy.

@ast

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy.

@en

P1433

Q35130437-09929FD3-2AF9-4B0D-942F-3374F0C89BF2

P1476

Q35130437-428EA648-65D0-4519-BF1C-094A13F55F57

P2093

Q35130437-12768B07-B876-4EEB-9C0E-8DC66FDB104D

Q35130437-1EF881A0-4240-4BAD-AEA2-95E07C064355

Q35130437-25C93475-1779-4B9D-95C5-FACD5B8032E1

Q35130437-2CEBDC0C-83BF-4103-A68A-3596CE1452B2

Q35130437-5719EE9F-B80F-47B7-B987-7F5AF864DDF8

Q35130437-5E0AE950-14F2-4ADD-BC26-5F98FC62E724

Q35130437-73396560-2076-4375-AC17-89A5D121F222

Q35130437-7CBADFE4-1A5C-484E-BE88-939BD9761D5A

Q35130437-9F805728-A001-429A-8B05-39E2BB50AB28

Q35130437-A5AF3321-BD45-47A1-B9C0-9F7EBA8DAD5B

P2860

Q35130437-029630CA-BBBA-4E49-9270-B6325C10C1FF

Q35130437-0A798A1F-F675-400C-92CC-C58AD8C43B1B

Q35130437-0B65F110-50D9-44B9-9AEC-21D280F3D4F6

Q35130437-0D5CE033-6F00-4338-BDF2-9543B73BDD5E

Q35130437-12377AE1-C87A-42BE-8581-E439B26D8706

Q35130437-15ED0BC9-2C22-485F-97C5-AC029C679F9A

Q35130437-20C0652D-1220-4C68-9FE9-25CDC523FDE8

Q35130437-24360346-71D9-4844-B7C5-3E1C5622BCCA

Q35130437-2F869D9E-92A1-4117-A7AB-E58F8F29F216

Q35130437-343CDA36-7343-4F85-8EF1-8032531597AD

P304

Q35130437-B4C901A6-9DB1-4257-BCC9-C4ECC9D824A6

P31

Q35130437-501C99F0-19F6-4BD3-AE06-E630472DEC85

P356

Q35130437-7E294D8E-7AEB-43F8-B7E7-FA5BED97697A

P407

Q35130437-3356D05E-A3ED-4A0E-9ABC-A8440E588D9D

P433

Q35130437-99CB6D01-27A7-41FC-A776-BB6C516591DD

P478

Q35130437-55586528-19C0-4AAD-A79F-CC747B9B5E30

P50

Q35130437-27CB7102-2C39-4433-9E5F-E7556F11A724

P577

Q35130437-C21BE5F9-571D-4B05-9C0A-9979CC20E5D5

P5875

Q35130437-1416FC2F-896D-4A44-B1B7-27140CD77623

P698

Q35130437-5BDCCEED-8687-4FE5-8B35-151C98DD041A

P932

Q35130437-0D9CD8C8-F6D5-47B5-803D-D3039EB5FC27

P356

1078-0432.CCR-06-0021

P1433

Clinical Cancer Research

P1476

Focal adhesion kinase targetin ...... for ovarian carcinoma therapy

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Aparna A Kamat

http://www.w3.org/2001/XMLSchema#string

Charles N Landen

http://www.w3.org/2001/XMLSchema#string

David M Gershenson

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Jyotsnabaran Halder

http://www.w3.org/2001/XMLSchema#string

Liz Y Han

http://www.w3.org/2001/XMLSchema#string

Nicholas B Jennings

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

Rosemarie Schmandt

http://www.w3.org/2001/XMLSchema#string

P2860

Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.

Differential regulation of cell motility and invasion by FAK

FAK integrates growth-factor and integrin signals to promote cell migration

Signaling through focal adhesion kinase

Biochemical signals and biological responses elicited by the focal adhesion kinase

CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase

Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples

CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells

Focal adhesion kinase: in command and control of cell motility

Cancer statistics, 2005

P304

4916-4924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-0021

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Arturo Chavez-Reyes

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6872485

http://www.w3.org/2001/XMLSchema#string

P698

16914580

http://www.w3.org/2001/XMLSchema#string

P932

3144499

http://www.w3.org/2001/XMLSchema#string